Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Pfizer Eyes $100 Million Expansion, New Jobs in North Carolina March 7, 2017 Merit Medical Coughs Up $100M for Bard, BD's Biopsy Assets November 15, 2017 Cipher Pharma Announces Amendment To Debt Agreement And Partial Prepayment April 2, 2017